CoMMit-Myeloma Trial Innovated

Aggregating investigators, patients and private entities to develop better therapies through efficient and patient-centered clinical trials

[Luciano J Costa @End_myeloma]

I believe second milestone is clear. we must do the work to finish the journey. #mmsm @ESHaematology @CoMMitTrials

[CoMMit-Myeloma Trial Innovated @CoMMitTrials]

***COMMIT Publication Alert***
British Journal of Haematology | Wiley Online Library https://t.co/dmtStZK9X0

[CoMMit-Myeloma Trial Innovated @CoMMitTrials]

**CoMMit Publication** Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy https://t.co/d5CArTirm7

[CoMMit-Myeloma Trial Innovated @CoMMitTrials]

Together we have accrued>160 #mmsm patients to transformative CoMMit trials in 2025!! Breakthroughs are on reach, and it will need your support. Please donate https://t.co/Uz3JaaU6i3

[Luciano J Costa @End_myeloma]

In @CoMMitTrials we are testing Tec-Dara as consolidation-maintenance, fixed duration, steroid free. Hoping to prevent progression from happening in first place. @MyelomaTeacher @grpetersen1

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#ASH25 not many investigator meetings look like this, but the @CoMMitTrials meeting thanks to @End_myeloma!

🍷 not shown, nor the 🛩️ Luciano has earned.

Look for many innovative trial results coming soon, including MASTER-2 with MRD-guided decision-making!

[CoMMit-Myeloma Trial Innovated @CoMMitTrials]

Productive evening conspiring against myeloma. This fantastic group accrued >150 patients in MM treatment trials in 2025. Several key colleagues couldn't make to MCO, will join us next year.

[CoMMit-Myeloma Trial Innovated @CoMMitTrials]

Commit crew dissecting #ASH25 data and planing the next generation of myeloma trials. Let's keep pushing! @RahulBanerjeeMD

[CoMMit-Myeloma Trial Innovated @CoMMitTrials]

@SusanBal9 et al published this exactly. The effect of ASCT on MRD is well known and can be used as benchmark for novel consolidation therapies
https://t.co/MtKrMCyMxL

[Raj Chakraborty @rajshekharucms]

While single-arm, the 100% MRD-negativity at 10^-6 with short course of Linvosiltemab post-induction is striking! Awaiting the FASTER RCT [Elra vs ASCT] from @CoMMitTrials but hard to imagine Mel-200 will achieve such high MRD-conversion rate based on prior data!
#ASH25

[CoMMit-Myeloma Trial Innovated @CoMMitTrials]

Happy Giving Tuesday! Get to know our group and our mission and, if you like it, consider giving your support. https://t.co/Uz3JaaTysv

[CoMMit-Myeloma Trial Innovated @CoMMitTrials]

@RahulBanerjeeMD @End_myeloma @SusanBal9

[CoMMit-Myeloma Trial Innovated @CoMMitTrials]

All CoMMit active trials and past research is now in one place. Learn more about and support our work. https://t.co/bgzUu1YNeE